Summary "compounds used as diacylglycerol acyltransferase inhibitors" This invention relates to novel compounds which are acyl coenzyme inhibitors to: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation and to its use in therapy, alone or in combination, with weight control or other triglyceride reduction therapies for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat activity -1 may have therapeutic benefit including, but not limited to obesity, obesity-related disorders, genetic (hyperlipidemia type 1, type 5) and acquired disorders of hypertriglyceridemia or hyperlipoproteinemia, caused but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplantation) and other factors ez, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, steato nonalcoholic hepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular disorder, angina, excessive hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis, such as such as myocardial, renal and hepatic fibrosis, hepatitis c acne infection, or other skin disorders.resumo “compostos utilizados como inibidores da diacilglicerol aciltransferase” esta invenção está relacionada a novos compostos que são inibidores da acil coenzima a: diacilglicerol aciltransferase 1 (dgat-1), a composições farmacêu-ticas que os contenham, a processos de sua preparação e a seu uso na terapia, so-zinha ou combinada, com terapias de controle de peso ou outras terapias de redu-ção de triglicerídeos para a prevenção ou tratamento de doenças relacionados à dis-função da dgat-1 ou onde a modulação da atividade da dgat-1 pode apresentar benefício terapêutico incluindo, mas não limitado a obesidade, distúrbios relaciona-dos à obesidade, formas genéticas (hiperlipidemia tipo 1, tipo 5) e adquiridas de dis-túrbios r
